argenx (ARGX) Q2 2026 earnings summary

Executive summary

• Achieved $1.5 billion in global product net sales in Q2 2026, up 60% year-over-year and 17% quarter-over-quarter, driven by strong VYVGART performance in MG and CIDP, and expansion into seronegative MG.

• Operating profit reached $494 million for the quarter, up 146% year-over-year.

• Ended Q2 2026 with $5.2 billion in cash, cash equivalents, and current financial assets.

• Expanded VYVGART and VYVGART Hytrulo label to cover all gMG serotypes, broadening patient reach and showing strong commercial momentum in MG and CIDP.

• Vision 2030 strategy aims to treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates into registrational development by 2030.

Financial highlights

• Q2 2026 product net sales reached $1.5 billion, up 60% year-over-year and 17% quarter-over-quarter.

• U.S. net sales were $1.3 billion, Japan $102 million (including a $25 million one-off benefit), rest of world $136 million, and $5 million from China supply.

• Operating profit for Q2 2026 was $494 million, up from $201 million in Q2 2025.

• Profit for Q2 2026: $472 million; H1 2026: $838 million (H1 2025: $415 million loss).

• Cash, cash equivalents, and current financial assets totaled $5.2 billion as of June 30, 2026.

Outlook and guidance

• Expect continued consistent growth trajectory for the remainder of 2026, with seronegative MG and potential ocular MG approval as growth drivers.

• Registrational study readouts for autoimmune myositis (Q3 2026) and MMN (Q4 2026) expected.

• Preparing for launches in autoimmune myositis and ocular MG, with ongoing investments in commercialization and field force expansion.

• Advancing five late-stage molecules by 2030, with next-gen FcRn assets and oral FcRn in development.

• VYVGART SC autoinjector launch planned for 2027 for all approved indications.